Delivery Order SPE2DB22D2005-SPE2DB25FJLP7
- Not listed
- The Defense Logistics Agency (DLA) awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Scemblix 40 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 3, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on April 29, 2025, for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, which must be completed by May 20, 2025, represents a competitively awarded, non-set-aside procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 tablets of Scemblix 40 mg, a pharmaceutical product, with completion scheduled for July 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency awarded a $13,259.50 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Scemblix 40 mg tablets (60-count units). This competitively awarded, non-set-aside contract is scheduled for completion by September 9, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, issued on August 22, 2025, with an ultimate completion date of September 15, 2025, represents a competitively awarded, non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Scemblix 40 mg tablets in quantities of 60 units. This firm fixed-price, competitively awarded contract carries an ultimate completion date of September 26, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $39,778.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Scemblix 40 mg tablets (60-count units). The contract, which is not set-aside and was competitively awarded, is scheduled for completion by October 16, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Scemblix 40 mg tablets (60-count units) with a contract ceiling value of $39,778.50. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The contract is set to be completed by September 17, 2025, and performance will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for supply of Scemblix 40 mg tablets (60 count) on September 5, 2025, with completion targeted for September 26, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Scemblix 40 mg tablets (60-unit bottles) with a ceiling value of $13,259.50. This firm fixed-price delivery order is scheduled for completion by October 15, 2025, and represents fulfillment under a larger contract vehicle. The award was not designated as a set-aside and was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJLP7Delivery Order
The Defense Logistics Agency (DLA) awarded a $13,259.50 delivery order contract to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price arrangement. The contract, awarded on April 25, 2025, with an ultimate completion date of May 16, 2025, was not set aside for small business concerns and was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The DLA has positioned this contract as part of its strategic approach to medical supply chain management, with plans to establish Pharmaceutical Prime Vendor Global Program Generation V contracts involving multiple regional awards across different contractors, thereby ensuring robust pharmaceutical support for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.3k | 4/25/25 |